Kintor Pharmaceutical (HKSE:09939) Cash And Cash Equivalents : HK$487.28 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Cash And Cash Equivalents?

Kintor Pharmaceutical's quarterly cash and cash equivalents declined from Dec. 2022 (HK$966.05 Mil) to Jun. 2023 (HK$756.15 Mil) but then stayed the same from Jun. 2023 (HK$756.15 Mil) to Dec. 2023 (HK$487.28 Mil).

Kintor Pharmaceutical's annual cash and cash equivalents declined from Dec. 2021 (HK$1,138.94 Mil) to Dec. 2022 (HK$966.05 Mil) and declined from Dec. 2022 (HK$966.05 Mil) to Dec. 2023 (HK$487.28 Mil).

Kintor Pharmaceutical Cash And Cash Equivalents Historical Data

The historical data trend for Kintor Pharmaceutical's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Cash And Cash Equivalents Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

217.58

1,263.18

1,138.94

966.05

487.28

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial						1,138.94	395.34	966.05	756.15	487.28

Kintor Pharmaceutical Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Kintor Pharmaceutical (HKSE:09939) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Kintor Pharmaceutical Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical (HKSE:09939) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

KNTPF:USA

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.

Executives

Tong Youzhi	2101 Beneficial owner
Kt International Investment Limited	2101 Beneficial owner
Guo Chuangxing	2201 Interest of corporation controlled by you
Kg Development Limited	2101 Beneficial owner
Nomura Holdings, Inc.	2201 Interest of corporation controlled by you
Tong Youzhi	2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si	2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si	2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si	2101 Beneficial owner

Kintor Pharmaceutical (HKSE:09939) Headlines

No Headlines